Freshfields advises MYR on acquisition by Gilead
Freshfields Bruckhaus Deringer ('Freshfields') has advised the current shareholders of MYR GmbH on the announced complete acquisition by Gilead Sciences, Inc. MYR GmbH is a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis delta virus (HDV). Both firms earlier today announced that MYR will be acquired by Gilead, the latter will pay MYR's owner approximately €1.15 billion in cash, payable upon closing of the transaction plus a potential future milestone payment of up to €300 million.
Freshfields advised the current owners of MYR on all legal aspects of the transaction, including the preparation and negotiation of the transaction documentation as well as tax and anti-trust matters.
The Freshfields team was led by Jochen Dieselhorst, Lars Meyer and Eva-Maria Hoyler. It also comprised Stephanie Hundertmark, Maximilian Hobuß, Marius Scherb and Xiaoguang Cai (all Corporate); Frank Röhling, Thomas Lübbig, Miriam Geiß and Ilka Mauelshagen as well as Mary Lehner, Laura Collins (both Washington) and Aude Guyon (Paris) – all Competition; Christian Ruoff, Tobias Franz and Andrea Strackerjan (all Tax).